Table 1 Baseline characteristics of study population
Variables | Survivors (n = 2385) | Non-survivors (n = 404) | p-value |
|---|---|---|---|
Demographics | Â | Â | Â |
 Age, years | 68.8 ± 11.4 | 74.5 ± 11.8 | < 0.001 |
 Age ≥ 75 years, n (%) | 741 (31.1) | 216 (53.5) | < 0.001 |
 Female, n (%) | 680 (28.5) | 159 (39.4) | < 0.001 |
 Body mass index, kg/m2 | 29.5 ± 5.9 | 28.8 ± 7.2 | 0.115 |
Vital signs | Â | Â | Â |
 Systolic blood pressure, mmHg | 118.8 ± 21.6 | 120.8 ± 25.2 | 0.124 |
 Diastolic blood pressure, mmHg | 63.7 ± 15.5 | 66.7 ± 19.6 | 0.003 |
 Heart rate, bpm | 82.3 ± 14.4 | 87.6 ± 19.7 | < 0.001 |
Comorbidities | Â | Â | Â |
 AMI, n (%) | 1176 (49.3) | 304 (75.2) | < 0.001 |
 Hypertension, n (%) | 1908 (80.0) | 348 (86.1) | 0.005 |
 Diabetes, n (%) | 1112 (46.6) | 214 (53.0) | 0.021 |
 History of MI, n (%) | 399 (16.7) | 61 (15.1) | 0.457 |
 Chronic heart failure, n (%) | 887 (37.2) | 262 (64.9) | < 0.001 |
 Peripheral vascular disease, n (%) | 368 (15.4) | 88 (21.8) | 0.002 |
 Cerebrovascular disease, n (%) | 329 (13.8) | 113 (28.0) | < 0.001 |
 Chronic kidney disease, n (%) | 722 (30.3) | 263 (65.1) | < 0.001 |
Treatment during hospitalization | Â | Â | Â |
 Antiplatelets, n (%) | 2055 (86.2) | 331 (82.1) | 0.038 |
 Statins, n (%) | 1838 (77.1) | 298 (73.9) | 0.187 |
 ACEIs/ARBs, n (%) | 648 (27.2) | 90 (22.3) | 0.048 |
 Beta-blockers, n (%) | 1240 (52.0) | 216 (53.6) | 0.593 |
 Vasoactive drugs, n (%) | 1572 (65.9) | 258 (63.9) | 0.456 |
 Insulin, n (%) | 1405 (58.9) | 230 (56.9) | 0.489 |
 Other antidiabetic drugs, n (%) | 160 (6.7) | 12 (3.0) | 0.005 |
 Renal replacement therapy, n (%) | 103 (4.3) | 79 (19.6) | < 0.001 |
 Ventilation, n (%) | 1885 (79.0) | 288 (71.3) | 0.001 |
Laboratory measurements | Â | Â | Â |
 Serum creatinine, mg/dL | 1.0 (0.8–1.3) | 1.4 (1.0–2.0) | < 0.001 |
 eGFR, mL/min/1.73m2 | 76.3 (55.9–96.4) | 48.4 (32.5–68.5) | < 0.001 |
 White blood cells, 109/L | 10.8 (7.9–14.6) | 11.7 (8.6–15.8) | 0.005 |
 Hemoglobin, g/dL | 11.0 ± 2.5 | 10.7 ± 2.3 | 0.034 |
 Platelets, 109/L | 196.4 ± 82.4 | 223.1 ± 102.3 | < 0.001 |
 Glucose, mg/dL | 137.0 (115.0-178.0) | 178.0 (133.5–260.0) | < 0.001 |
 HbA1c, % | 6.6 ± 1.6 | 6.6 ± 1.5 | 0.453 |
 SHR, (mean ± standard deviation) | 1.1 ± 0.5 | 1.3 ± 0.6 | < 0.001 |
 GV, % | 20.0 (12.9–30.6) | 25.2 (16.9–36.7) | < 0.001 |
 Length of ICU stay, days | 3.0 (2.0–4.0) | 4.0 (2.0–7.0) | < 0.001 |
 SOFA score, (mean ± standard deviation) | 5.0 (3.0–7.0) | 6.0 (4.0–8.0) | < 0.001 |